Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria
Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis [FSGS], treatment-resistant minimal change disease [TR MCD], primary immunoglobulin A nephropathy [IgAN], and primary membranous nephropathy [PMN]). Subjects in this study will be randomized to receive the investigational drug WAL0921 or placebo as an intravenous infusion once every 2 weeks for 7 total infusions. All subjects will be followed for 24 weeks after their last infusion.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@waldenbiosciences.com8573141961
Hinsdale, Illinois 60521, United States
Sambhajinagar, Maharashtra 431003, India
New Delhi, National Capital Territory of Delhi 110060, India
Patparganj, National Capital Territory of Delhi 110092, India
Lucknow, Uttar Pradesh 226014, India
Dehradun, Uttarakhand 248001, India
Cheras, Kuala Lumpur 56000, Malaysia
clinicaltrials@waldenbiosciences.com+18573141961
clinicaltrials@waldenbiosciences.com+18573141961
clinicaltrials@waldenbiosciences.com+1 857 314 1961
clinicaltrials@waldenbiosciences.com+1 8573141961
clinicaltrials@waldenbiosciences.com+1 8573141961
clinicaltrials@waldenbiosciences.com+1 8573141961